What is the quarterly run rate of the revenues from divestitures that have already closed, as mentioned in the prepared comments 
ve the right platform for that. So we are investing some money in our basic platform, our basic infrastructure, IT, finance, all of that to make sure that if we did participate in that, that we could integrate a company very well and move forward. So we've been doing some of that. We'll do more of it. And then more broadly, obviously, there's continuous innovation in this industry.
We are the largest player in the industry. So scale is always helpful, additional scale. But for us, it's probably more around technologies, and there's three of them. There's printing, there's materials and there's software. So those three will encompass our focus.
And I would again come back, Greg, to biotech. I just think -- I think the next horizon for additive manufacturing, there's an enormous runway for current applications in both industrial and Health care. But when you look out past those, there is a whole new horizon on biotech for printing. And I'm really excited to be making -- to position ourselves well for that market as well. So hopefully, from our shareholder standpoint, investors, the very short term -- good short-term benefits by growth in the existing markets and the adoption of additive for healthcare and industrial and then you provide a long-term value play in the biomedical space, biotech space with regenerative medicine. Does that make sense?
Greg Palm -- Craig-Hallum -- Analyst
Yes. All good. Appreciate all the insight. Thanks. I'll hop back in queue.
Jeffrey A. Graves -- Chief Executive Officer and President
Thanks, Greg.
Operator
Thank you. Our next question is coming from Sarkis Sherbetchyan of B. Riley FBR. Please go ahead.
Sarkis Sherbetchyan -- B. Riley FBR -- Analyst
Hey, good morning and thank you for taking my question here.
Jeffrey A. Graves -- Chief Executive Officer and President
Good morning, Sarkis.
Sarkis Sherbetchyan -- B. Riley FBR -- Analyst
Yes. So first question just really revolves around the revenue from divestitures that's called out for both fiscal '19 and '20 on the bottom of the release. I think it sum totals to, let's call it, a range of $40 million to $50 million on the year. But in the prepared comments, I think you mentioned the quarterly run rate of the revenues from divestitures are $25 million. So that adds up to $100 million. So I just wanted to get a sense if the revenues called out in the press release were from GibbsCAM, Cimatron and the other revenues that you called out in the earnings deck. Is that for the businesses pending divestiture in 3Q?
Jagtar Narula -- Executive Vice President, Chief Financial Officer
Yes. Sarkis, you got that exactly right. So what's called out in the release is to reconcile to organic growth. So those are only the acquisitions that have already closed -- or sorry, the divestitures have already closed, which is GibbsCAM, Cimatron and a couple of small divestitures that we did last year, our ODM business in China and Australia, and that's the $40 million to $50 million that you're referencing of revenue.
The $25 million I referenced in my prepared remarks are for the divestitures that we have not yet closed. That's the on-demand parts business and the Simbionix business. And we expect that to close midway through the second quarter at some point versus third quarter at some point.
Sarkis Sherbetchyan -- B. Riley FBR -- Analyst
Okay. So just to use some crude math here, if I simply take the sum total of the '19 as a base line, right, ex the divestitures and then remove about $100 million in top line, I get to about $500 million or so in, let's call it, pro forma top line. We should grow the business from that point forward and then kind of take your margin range of, I think you said 40% to 44% still and kind of work with that, correct?
Jagtar Narula -- Executive Vice President, Chief Financial Officer
Yes, that's absolutely correct. That's -- I think I mentioned in my prepared remarks that we would expect to be in the order of $500 million revenue company post divestitures, profitable. And so I think you've got it exactly right.
Sarkis Sherbetchyan -- B. 
ve the right platform for that. So we are investing some money in our basic platform, our basic infrastructure, IT, finance, all of that to make sure that if we did participate in that, that we could integrate a company very well and move forward. So we've been doing some of that. We'll do more of it. And then more broadly, obviously, there's continuous innovation in this industry.
We are the largest player in the industry. So scale is always helpful, additional scale. But for us, it's probably more around technologies, and there's three of them. There's printing, there's materials and there's software. So those three will encompass our focus.
And I would again come back, Greg, to biotech. I just think -- I think the next horizon for additive manufacturing, there's an enormous runway for current applications in both industrial and Health care. But when you look out past those, there is a whole new horizon on biotech for printing. And I'm really excited to be making -- to position ourselves well for that market as well. So hopefully, from our shareholder standpoint, investors, the very short term -- good short-term benefits by growth in the existing markets and the adoption of additive for healthcare and industrial and then you provide a long-term value play in the biomedical space, biotech space with regenerative medicine. Does that make sense?
Greg Palm -- Craig-Hallum -- Analyst
Yes. All good. Appreciate all the insight. Thanks. I'll hop back in queue.
Jeffrey A. Graves -- Chief Executive Officer and President
Thanks, Greg.
Operator
Thank you. Our next question is coming from Sarkis Sherbetchyan of B. Riley FBR. Please go ahead.
Sarkis Sherbetchyan -- B. Riley FBR -- Analyst
Hey, good morning and thank you for taking my question here.
Jeffrey A. Graves -- Chief Executive Officer and President
Good morning, Sarkis.
Sarkis Sherbetchyan -- B. Riley FBR -- Analyst
 Yes. So first question just really revolves around the revenue from divestitures that's called out for both fiscal '19 and '20 on the bottom of the release. I think it sum totals to, let's call it, a range of $40 million to $50 million on the year. But in the prepared comments, I think you mentioned the quarterly run rate of the revenues from divestitures are $25 million. So that adds up to $100 million. So I just wanted to get a sense if the revenues called out in the press release were from GibbsCAM, Cimatron and the other revenues that you called out in the earnings deck. Is that for the businesses pending divestiture in 3Q?
Jagtar Narula -- Executive Vice President, Chief Financial Officer
Yes. Sarkis, you got that exactly right. So what's called out in the release is to reconcile to organic growth. So those are only the acquisitions that have already closed -- or sorry, the divestitures have already closed, which is GibbsCAM, Cimatron and a couple of small divestitures that we did last year, our ODM business in China and Australia, and that's the $40 million to $50 million that you're referencing of revenue.
The $25 million I referenced in my prepared remarks are for the divestitures that we have not yet closed. That's the on-demand parts business and the Simbionix business. And we expect that to close midway through the second quarter at some point versus third quarter at some point.
Sarkis Sherbetchyan -- B. Riley FBR -- Analyst
Okay. So just to use some crude math here, if I simply take the sum total of the '19 as a base line, right, ex the divestitures and then remove about $100 million in top line, I get to about $500 million or so in, let's call it, pro forma top line. We should grow the business from that point forward and then kind of take your margin range of, I think you said 40% to 44% still and kind of work with that, correct?
Jagtar Narula -- Executive Vice President, Chief Financial Officer
Yes, that's absolutely correct. That's -- I think I mentioned in my prepared remarks that we would expect to be in the order of $500 million revenue company post divestitures, profitable. And so I think you've got it exactly right.
 Sarkis Sherbetchyan -- B. 